Supplementary Material for: Monotherapy of PD-1 inhibitor camrelizumab reverses advanced lung squamous cell carcinoma with low PD-1 expression: a case report

Introduction: Chemotherapy plus immunotherapy is the standard treatment worldwide for advanced lung squamous cell carcinoma with high programed cell death protein-1 (PD-1) expression. The use of immunotherapy alone against advanced lung squamous cell carcinoma is rarely reported and data on PD-1 inhibitor camrelizumab is missing. We report the first case of camrelizumab monotherapy, which can be a reference for the clinical applications of camrelizumab in a wider context. Case Presentation: We herein present a 69-year-old male case of advanced squamous cell carcinoma with low PD-1 expression, in which camrelizumab monotherapy was administered every 3 weeks. Camrelizumab monotherapy reversed advanced lung squamous cell carcinoma without recurrence or obvious side effects during 26 months of follow-up. The patient is alive and in good conditions to date, thus progression-free survival (PFS) and overall survival (OS) are not determined. Conclusion: This case report provides evidence of the efficacy of camrelizumab monotherapy, and highlight the feasibility of camrelizumab alone against advanced lung squamous cell carcinoma when chemotherapy is not applicable.